UNASSIGNED: This nested case-control study used data from the National Health Insurance Service database to analyze 2017 data from women aged ≥50 years and diagnosed with natural menopause between 2004 and 2007. Among 356,160 eligible women, 36,446 used HRT for ≥1 year and 319,714 did not (controls). These two groups were matched 1:1 for statistical analysis. Type and duration were categorized into three categories.
UNASSIGNED: Women who started estrogen-progestogen therapy (EPT) or estrogen therapy (ET) in their 50s, or EPT or tibolone in their ≥60s exhibited a lower stroke risk than controls. MI risk was lower among women who used tibolone - regardless of duration - or EPT or ET for 1-3 years than among controls. Stroke risk was lower with tibolone use for ≥5 years or with EPT or ET use for 1-3 years or ≥5 years than non-users.
UNASSIGNED: Our study may support the beneficial effect of HRT by showing that Korean postmenopausal women who used HRT at a relatively younger and healthier age had a relative benefit for MI and stroke.
■这项嵌套病例对照研究使用了国家健康保险服务数据库中的数据,以分析2004年至2007年间年龄≥50岁并被诊断为自然更年期的女性的2017年数据。在356,160名符合条件的妇女中,36,446人使用HRT≥1年,319,714人没有使用(对照)。两组以1:1进行统计学分析。类型和持续时间分为三类。
■50多岁开始雌激素-孕激素治疗(EPT)或雌激素治疗(ET)的女性,≥60岁的EPT或替勃龙的卒中风险低于对照组。与对照组相比,使用替勃龙-无论持续时间如何-或EPT或ET1-3年的女性的MI风险较低。使用替勃龙≥5年或使用EPT或ET1-3年或≥5年的卒中风险低于非使用者。
■我们的研究可能支持HRT的有益效果,因为我们的研究表明,在相对较年轻和健康的年龄使用HRT的韩国绝经后妇女对MI和中风有相对益处。